Problems and Possible Solutions for Therapy with Statins

 

 Buy Article Permissions and Reprints

Abstract

Despite issues about the value of statins, benefit for high cardiovascular (CV) risk outweighs problems. However, the practitioner must be aware of concerns, be prepared to respond, and justify statin usage. Symptoms of statin-related myopathy are of more concern than stated by pharmaceutical companies. Occurrence of myopathy symptoms, estimated to be up to 10.4%, can decrease statin adherence of high CV risk patients. Dosage modification, or use of pitavastatin, may help the problematic patient. There are concerns that there may be little benefit of statins for primary prevention in women. However, evidence appears to support statin use in women at high CV risk, both in primary and secondary prevention. Abandoning low-density lipoprotein cholesterol (LDL-C) as a valid target is unwarranted; there is much evidence to support “lower is better.” The practitioner must be aware of the complicated processes causing atherosclerosis and when to incorporate new approaches to disease management. Tailoring therapy for CV risk, when indicated, may contribute further to LDL-C reduction. Liver inflammation can occur with statins but is of minimal concern; frequently, statins alleviate the problem. Unless liver transaminases are over three times normal, a statin should be prescribed, if indicated. The net effect of statins on cognition appears to be zero—no harm, no benefit. Despite reports of improved cognition, statins should not be prescribed for this. With diabetes mellitus (DM), statins can increase incidence, but the CV benefit far outweighs any risk. Therefore, statins should be prescribed in DM to reduce CV risk. Statins are a major medical contribution when used appropriately.

• References

• 1 Whayne Jr TF. Statin myopathy: significant problem with minimal awareness by clinicians and no emphasis by clinical investigators. Angiology 2011; 62 (5) 415-421
  CrossrefPubMedGoogle Scholar
• 2 Silva MA, Swanson AC, Gandhi PJ, Tataronis GR. Statin-related adverse events: a meta-analysis. Clin Ther 2006; 28 (1) 26-35
  CrossrefPubMedGoogle Scholar
• 3 Walsh JM, Pignone M. Drug treatment of hyperlipidemia in women. JAMA 2004; 291 (18) 2243-2252
  CrossrefPubMedGoogle Scholar
• 4 Hayward RA, Krumholz HM. Three reasons to abandon low-density lipoprotein targets: an open letter to the Adult Treatment Panel IV of the National Institutes of Health. Circ Cardiovasc Qual Outcomes 2012; 5 (1) 2-5
  CrossrefPubMedGoogle Scholar
• 5 Whayne Jr TF. Assessment of low-density lipoprotein targets. Angiology 2012; Jun 25. [Epub ahead of print], PMID: 22734087 [PubMed- as supplied by publisher].
  PubMedGoogle Scholar
• 6 National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106 (25) 3143-3421
  PubMedGoogle Scholar
• 7 McGuinness B, O'Hare J, Craig D, Bullock R, Malouf R, Passmore P. Statins for the treatment of dementia. Cochrane Database Syst Rev 2010; (8) CD007514
  PubMedGoogle Scholar
• 8 Sattar N, Preiss D, Murray HM , et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010; 375 (9716) 735-742
  CrossrefPubMedGoogle Scholar
• 9 Ghatak A, Faheem O, Thompson PD. The genetics of statin-induced myopathy. Atherosclerosis 2010; 210 (2) 337-343
  CrossrefPubMedGoogle Scholar
• 10 Phillips PS, Haas RH, Bannykh S , et al; Scripps Mercy Clinical Research Center. Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med 2002; 137 (7) 581-585
  CrossrefPubMedGoogle Scholar
• 11 Nissen SE, Tuzcu EM, Schoenhagen P , et al; REVERSAL Investigators. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004; 291 (9) 1071-1080
  CrossrefPubMedGoogle Scholar
• 12 Cannon CP, Braunwald E, McCabe CH , et al; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350 (15) 1495-1504
  CrossrefPubMedGoogle Scholar
• 13 Nissen SE, Nicholls SJ, Sipahi I , et al; ASTEROID Investigators. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006; 295 (13) 1556-1565
  CrossrefPubMedGoogle Scholar
• 14 Josan K, Majumdar SR, McAlister FA. The efficacy and safety of intensive statin therapy: a meta-analysis of randomized trials. CMAJ 2008; 178 (5) 576-584
  CrossrefPubMedGoogle Scholar
• 15 Bruckert E, Hayem G, Dejager S, Yau C, Bégaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients—the PRIMO study. Cardiovasc Drugs Ther 2005; 19 (6) 403-414
  CrossrefPubMedGoogle Scholar
• 16 Pablos-Méndez A, Barr RG, Shea S. Run-in periods in randomized trials: implications for the application of results in clinical practice. JAMA 1998; 279 (3) 222-225
  CrossrefPubMedGoogle Scholar
• 17 Gazi IF, Daskalopoulou SS, Nair DR, Mikhailidis DP. Effect of ezetimibe in patients who cannot tolerate statins or cannot get to the low density lipoprotein cholesterol target despite taking a statin. Curr Med Res Opin 2007; 23 (9) 2183-2192
  CrossrefPubMedGoogle Scholar
• 18 Sager PT, Melani L, Lipka L , et al; Ezetimibe Study Group. Effect of coadministration of ezetimibe and simvastatin on high-sensitivity C-reactive protein. Am J Cardiol 2003; 92 (12) 1414-1418
  CrossrefPubMedGoogle Scholar
• 19 Crane FL. Biochemical functions of coenzyme Q10. J Am Coll Nutr 2001; 20 (6) 591-598
  CrossrefPubMedGoogle Scholar
• 20 Gadarla M, Kearns AK, Thompson PD. Efficacy of rosuvastatin (5.  mg and 10 mg) twice a week in patients intolerant to daily statins. Am J Cardiol 2008; 101 (12) 1747-1748
  CrossrefPubMedGoogle Scholar
• 21 Kawashiri MA, Nohara A, Tada H , et al. Comparison of effects of pitavastatin and atorvastatin on plasma coenzyme Q10 in heterozygous familial hypercholesterolemia: results from a crossover study. Clin Pharmacol Ther 2008; 83 (5) 731-739
  CrossrefPubMedGoogle Scholar
• 22 Gupta A, Thompson PD. The relationship of vitamin D deficiency to statin myopathy. Atherosclerosis 2011; 215 (1) 23-29
  CrossrefPubMedGoogle Scholar
• 23 LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA 1999; 282 (24) 2340-2346
  CrossrefPubMedGoogle Scholar
• 24 Culver AL, Ockene IS, Balasubramanian R , et al. Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative. Arch Intern Med 2012; 172 (2) 144-152
  CrossrefPubMedGoogle Scholar
• 25 Kostis WJ, Cheng JQ, Dobrzynski JM, Cabrera J, Kostis JB. Meta-analysis of statin effects in women versus men. J Am Coll Cardiol 2012; 59 (6) 572-582
  CrossrefPubMedGoogle Scholar
• 26 Gutierrez J, Ramirez G, Rundek T, Sacco RL. Statin therapy in the prevention of recurrent cardiovascular events: a sex-based meta-analysis. Arch Intern Med 2012; 172 (12) 909-919
  CrossrefPubMedGoogle Scholar
• 27 Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344 (8934) 1383-1389
  PubMedGoogle Scholar
• 28 The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339 (19) 1349-1357
  CrossrefPubMedGoogle Scholar
• 29 Shepherd J, Cobbe SM, Ford I , et al; West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333 (20) 1301-1307
  CrossrefPubMedGoogle Scholar
• 30 Downs JR, Clearfield M, Weis S , et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279 (20) 1615-1622
  CrossrefPubMedGoogle Scholar
• 31 Ray KK, Seshasai SR, Erqou S , et al. Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants. Arch Intern Med 2010; 170 (12) 1024-1031
  CrossrefPubMedGoogle Scholar
• 32 Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327 (7414) 557-560
  CrossrefPubMedGoogle Scholar
• 33 Redberg RF. Update in cardiology: evidence published in 2010. Ann Intern Med 2011; 154 (8) 549-553
  CrossrefPubMedGoogle Scholar
• 34 Ridker PM, Danielson E, Fonseca FA , et al; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359 (21) 2195-2207
  CrossrefPubMedGoogle Scholar
• 35 de Lorgeril M, Salen P, Abramson J , et al. Cholesterol lowering, cardiovascular diseases, and the rosuvastatin-JUPITER controversy: a critical reappraisal. Arch Intern Med 2010; 170 (12) 1032-1036
  CrossrefPubMedGoogle Scholar
• 36 Whayne Jr TF. Astronomical science or astronomical marketing?. Clin Geriatrics 2009; 17: 36
  PubMedGoogle Scholar
• 37 Green LA. Cholesterol-lowering therapy for primary prevention: still much we don't know. Arch Intern Med 2010; 170 (12) 1007-1008
  CrossrefPubMedGoogle Scholar
• 38 Brugts JJ, Yetgin T, Hoeks SE , et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ 2009; 338: b2376
  CrossrefPubMedGoogle Scholar
• 39 The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984; 251 (3) 351-364
  CrossrefPubMedGoogle Scholar
• 40 The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984; 251 (3) 365-374
  CrossrefPubMedGoogle Scholar
• 41 Blankenhorn DH, Johnson RL, Nessim SA, Azen SP, Sanmarco ME, Selzer RH. The Cholesterol Lowering Atherosclerosis Study (CLAS): design, methods, and baseline results. Control Clin Trials 1987; 8 (4) 356-387
  CrossrefPubMedGoogle Scholar
• 42 Blankenhorn DH, Nessim SA, Johnson RL, Sanmarco ME, Azen SP, Cashin-Hemphill L. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 1987; 257 (23) 3233-3240
  CrossrefPubMedGoogle Scholar
• 43 Buchwald H, Stoller DK, Campos CT, Matts JP, Varco RL. Partial ileal bypass for hypercholesterolemia. 20- to 26-year follow-up of the first 57 consecutive cases. Ann Surg 1990; 212 (3) 318-329 , discussion 329–331
  CrossrefPubMedGoogle Scholar
• 44 Buchwald H, Varco RL, Boen JR , et al. Effective lipid modification by partial ileal bypass reduced long-term coronary heart disease mortality and morbidity: five-year posttrial follow-up report from the POSCH. Program on the Surgical Control of the Hyperlipidemias. Arch Intern Med 1998; 158 (11) 1253-1261
  CrossrefPubMedGoogle Scholar
• 45 Moriarty PM. LDL-apheresis therapy. Curr Treat Options Cardiovasc Med 2006; 8 (4) 282-288
  CrossrefPubMedGoogle Scholar
• 46 Schonfeld G. The hypobetalipoproteinemias. Annu Rev Nutr 1995; 15: 23-34
  CrossrefPubMedGoogle Scholar
• 47 Wiviott SD, Cannon CP, Morrow DA, Ray KK, Pfeffer MA, Braunwald E. PROVE IT-TIMI 22 Investigators. Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy. J Am Coll Cardiol 2005; 46 (8) 1411-1416
  CrossrefPubMedGoogle Scholar
• 48 Athyros VG, Papageorgiou AA, Mercouris BR , et al. Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Curr Med Res Opin 2002; 18 (4) 220-228
  CrossrefPubMedGoogle Scholar
• 49 Hsia J, MacFadyen JG, Monyak J, Ridker PM. Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol <50 mg/dl with rosuvastatin. The JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). J Am Coll Cardiol 2011; 57 (16) 1666-1675
  CrossrefPubMedGoogle Scholar
• 50 Grundy SM, Cleeman JI, Merz CN , et al; National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110 (2) 227-239
  CrossrefPubMedGoogle Scholar
• 51 Pascale A, Pais R, Ratziu V. An overview of nonalcoholic steatohepatitis: past, present and future directions. J Gastrointestin Liver Dis 2010; 19 (4) 415-423
  PubMedGoogle Scholar
• 52 Athyros VG, Tziomalos K, Gossios TD , et al; GREACE Study Collaborative Group. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet 2010; 376 (9756) 1916-1922
  CrossrefPubMedGoogle Scholar
• 53 Han KH, Rha SW, Kang HJ , et al. Evaluation of short-term safety and efficacy of HMG-CoA reductase inhibitors in hypercholesterolemic patients with elevated serum alanine transaminase concentrations: PITCH study (PITavastatin versus atorvastatin to evaluate the effect on patients with hypercholesterolemia and mild to moderate hepatic damage). J Clin Lipidol 2012; 6 (4) 340-351
  CrossrefPubMedGoogle Scholar
• 54 Wierzbicki AS, Oben J. Nonalcoholic fatty liver disease and lipids. Curr Opin Lipidol 2012; 23 (4) 345-352
  CrossrefPubMedGoogle Scholar
• 55 Henninger C, Huelsenbeck J, Huelsenbeck S , et al. The lipid lowering drug lovastatin protects against doxorubicin-induced hepatotoxicity. Toxicol Appl Pharmacol 2012; 261 (1) 66-73
  CrossrefPubMedGoogle Scholar
• 56 Rzouq FS, Volk ML, Hatoum HH, Talluri SK, Mummadi RR, Sood GK. Hepatotoxicity fears contribute to underutilization of statin medications by primary care physicians. Am J Med Sci 2010; 340 (2) 89-93
  CrossrefPubMedGoogle Scholar
• 57 Biondi E. Prescription of lipophilic statins to Alzheimer's disease patients: some controversies to consider. Neurol Sci 2011; 32 (2) 195-201
  CrossrefPubMedGoogle Scholar
• 58 Rojas-Fernandez CH, Cameron JC. Is statin-associated cognitive impairment clinically relevant? A narrative review and clinical recommendations. Ann Pharmacother 2012; 46 (4) 549-557
  CrossrefPubMedGoogle Scholar
• 59 Li G, Shofer JB, Rhew IC , et al. Age-varying association between statin use and incident Alzheimer's disease. J Am Geriatr Soc 2010; 58 (7) 1311-1317
  CrossrefPubMedGoogle Scholar
• 60 Trompet S, van Vliet P, de Craen AJ , et al. Pravastatin and cognitive function in the elderly. Results of the PROSPER study. J Neurol 2010; 257 (1) 85-90
  CrossrefPubMedGoogle Scholar
• 61 Glasser SP, Wadley V, Judd S , et al. The association of statin use and statin type and cognitive performance: analysis of the reasons for geographic and racial differences in stroke (REGARDS) study. Clin Cardiol 2010; 33 (5) 280-288
  CrossrefPubMedGoogle Scholar
• 62 Sabbagh MN, Sparks DL. Statins to treat Alzheimer's disease: an incomplete story. Expert Rev Neurother 2012; 12 (1) 27-30
  CrossrefPubMedGoogle Scholar
• 63 Freeman DJ, Norrie J, Sattar N , et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 2001; 103 (3) 357-362
  CrossrefPubMedGoogle Scholar
• 64 Dalla Nora E, Passaro A, Zamboni PF, Calzoni F, Fellin R, Solini A. Atorvastatin improves metabolic control and endothelial function in type 2 diabetic patients: a placebo-controlled study. J Endocrinol Invest 2003; 26 (1) 73-78
  PubMedGoogle Scholar
• 65 Huptas S, Geiss HC, Otto C, Parhofer KG. Effect of atorvastatin (10 mg/day) on glucose metabolism in patients with the metabolic syndrome. Am J Cardiol 2006; 98 (1) 66-69
  CrossrefPubMedGoogle Scholar
• 66 Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet 2012; 380 (9841) 565-571
  CrossrefPubMedGoogle Scholar
• 67 Colbert JD, Stone JA. Statin use and the risk of incident diabetes mellitus: a review of the literature. Can J Cardiol 2012; 28 (5) 581-589
  CrossrefPubMedGoogle Scholar
• 68 Jukema JW, Cannon CP, de Craen AJ, Westendorp RG, Trompet S. The controversies of statin therapy: weighing the evidence. J Am Coll Cardiol 2012; 60 (10) 875-881
  CrossrefPubMedGoogle Scholar
• 69 Navarese EP, Buffon A, Andreotti F , et al. Meta-analysis of impact of different types and doses of statins on new-onset diabetes mellitus. Am J Cardiol 2013; Jan 24 [Epub ahead of print]. PMID: 23352266 [PubMed-as supplied by publisher].
  PubMedGoogle Scholar
• 70 Shah RV, Goldfine AB. Statins and risk of new-onset diabetes mellitus. Circulation 2012; 126 (18) e282-e284
  CrossrefPubMedGoogle Scholar
• 71 Rocco MB. Statins and diabetes risk: fact, fiction, and clinical implications. Cleve Clin J Med 2012; 79 (12) 883-893
  CrossrefPubMedGoogle Scholar